Search - tctmd.com

Displaying 201 - 220 of 432

Sort: Relevancy | Date

Presentation TCT 2018

Hypertension 2018 Update: From Ambulatory Monitoring to Definitional Controversies and More

Presenter: Vasilios Papademetriou, Paul A. Sobotka, Michael A. Weber

September 24, 2018

Presentation TCT 2018

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Presenter: John A. Bittl, Bernard J. Gersh, Michael A. Weber

September 24, 2018

Presentation TCT 2018

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, David E. Kandzari

September 23, 2018

Presentation TCT 2018

Point to Consider in the Review of the RDN Related Devices: US Regulatory

Presenter: Kenneth J. Cavanaugh Jr, Takafumi Ueno, Hiren Mistry

September 22, 2018

Presentation TCT 2018

Japanese Perspective and Experience on RDN Studies

Presenter: Kenneth J. Cavanaugh Jr, Takafumi Ueno

September 22, 2018

Presentation TCT 2018

The Overview of Current Evidence of RDN: The Result of RADIANCE-HTN SOLO Trial and SPYRAL HTN-on MED Trial

Presenter: Kenneth J. Cavanaugh Jr, Takafumi Ueno, Justin E. Davies

September 22, 2018

News Conference News TCT 2018

Untreated Accessory Arteries Dampen Renal Denervation Response: RADIANCE-HTN SOLO

Todd Neale

September 21, 2018

Presentation TCT 2018

TCT-31: Comparison of Standard Renal Denervation Procedure versus Novel Distal and Branch Vessel Procedure with Brachial Arterial Access

Presenter: Melvin D. Lobo, Ivo Petrov

September 21, 2018

Presentation TCT 2018

TCT-30: Renal Denervation Improves Cardiac Function in a Swine Model of Heart Failure

Presenter: Melvin D. Lobo, Ivo Petrov, Traci Goodchild

September 21, 2018

Presentation TCT 2018

TCT-29: Procedural and Anatomic Predictors of Response in RADIANCE-HTN SOLO: A Multicenter, Randomized, Sham-Controlled Trial Of Endovascular Ultrasound Renal Denervation

Presenter: Melvin D. Lobo, Ivo Petrov, Ajay J. Kirtane

September 21, 2018

Presentation TCT 2018

Renal Denervation: Light on the Horizon?

Presenter: Jeroen J. Bax, Stephan Windecker, Felix Mahfoud

September 21, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

Presentation TCT 2017

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Presenter: Hiren Mistry, Michael A. Weber

October 31, 2017

Presentation TCT 2017

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

Presenter: Hiren Mistry, Michael A. Weber, Michael Böhm

October 31, 2017

Presentation TCT 2017

Potential for Renal Denervation to Treat Chronic Systolic Heart Failure: REACH and More

Presenter: Daniel Burkhoff, JoAnn Lindenfeld, Justin E. Davies

October 31, 2017

Presentation TCT 2017

Pacemaker Mediated Hypertension Treatment (BackBeat): First-in-Man Results and Ongoing Plans

Presenter: Elazer R. Edelman, Paul A. Sobotka, Karl-Heinz Kuck

October 30, 2017

Presentation TCT 2017

AV-Fistula Creation (ROX Coupler): Extended Follow-up Results and Next Steps

Presenter: Elazer R. Edelman, Paul A. Sobotka, Krishna J. Rocha-Singh

October 30, 2017

Presentation TCT 2017

Transcatheter Carotid Body Denervation (Cibiem): First-in-Man Results and Future Directions

Presenter: Elazer R. Edelman, Paul A. Sobotka, Felix Mahfoud

October 30, 2017

Presentation TCT 2017

Carotid Body Endovascular Baroreflex Amplification (Vascular Dynamics MobiusHD): From CALM-FIM EUR to CALM II

Presenter: Elazer R. Edelman, Paul A. Sobotka, Mark C. Bates

October 30, 2017

Presentation TCT 2017

Targets for Device-Based Hypertension Treatments Beyond the Kidneys: Physiology Revisited

Presenter: Elazer R. Edelman, Paul A. Sobotka

October 30, 2017

Advertisement

Hypertension 2018 Update: From Ambulatory Monitoring to Definitional Controversies and More

REDUCE HTN: REINFORCE: A Sham-Controlled, Off-Med Randomized Trial of Renal Denervation for Treatment of Hypertension

Sham Controls in Renal Denervation Studies: Need to Have vs Nice to Have?

Point to Consider in the Review of the RDN Related Devices: US Regulatory

Japanese Perspective and Experience on RDN Studies

The Overview of Current Evidence of RDN: The Result of RADIANCE-HTN SOLO Trial and SPYRAL HTN-on MED Trial

Untreated Accessory Arteries Dampen Renal Denervation Response: RADIANCE-HTN SOLO

TCT-31: Comparison of Standard Renal Denervation Procedure versus Novel Distal and Branch Vessel Procedure with Brachial Arterial Access

TCT-30: Renal Denervation Improves Cardiac Function in a Swine Model of Heart Failure

TCT-29: Procedural and Anatomic Predictors of Response in RADIANCE-HTN SOLO: A Multicenter, Randomized, Sham-Controlled Trial Of Endovascular Ultrasound Renal Denervation

Renal Denervation: Light on the Horizon?

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

FDA Perspectives: Devices to Control Hypertension - Patient Populations, Endpoints and Other Considerations

Renal Denervation Trial Design Considerations: Challenges and Lessons Learned

Potential for Renal Denervation to Treat Chronic Systolic Heart Failure: REACH and More

Pacemaker Mediated Hypertension Treatment (BackBeat): First-in-Man Results and Ongoing Plans

AV-Fistula Creation (ROX Coupler): Extended Follow-up Results and Next Steps

Transcatheter Carotid Body Denervation (Cibiem): First-in-Man Results and Future Directions

Carotid Body Endovascular Baroreflex Amplification (Vascular Dynamics MobiusHD): From CALM-FIM EUR to CALM II

Targets for Device-Based Hypertension Treatments Beyond the Kidneys: Physiology Revisited

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content